Patents by Inventor Takahiko Tobe
Takahiko Tobe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9708307Abstract: A compound which is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM) is provided. The present inventors have studied a compound which has a dopamine D1 receptor positive allosteric modulating activity and is useful as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like, and they have thus found that a heterocyclic acetamide compound has a dopamine D1 receptor positive allosteric modulating activity, thereby completing the present invention. The heterocyclic acetamide compound of the present invention has a dopamine D1 receptor positive allosteric modulating activity and can be used as an agent for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like.Type: GrantFiled: October 28, 2014Date of Patent: July 18, 2017Assignee: Astellas Pharma Inc.Inventors: Ryota Shiraki, Takahiko Tobe, Shimpei Kawakami, Hiroyuki Moritomo, Makoto Ohmiya
-
Publication number: 20150045402Abstract: A compound which is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM) is provided. The present inventors have studied a compound which has a dopamine D1 receptor positive allosteric modulating activity and is useful as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like, and they have thus found that a heterocyclic acetamide compound has a dopamine D1 receptor positive allosteric modulating activity, thereby completing the present invention. The heterocyclic acetamide compound of the present invention has a dopamine D1 receptor positive allosteric modulating activity and can be used as an agent for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like.Type: ApplicationFiled: October 28, 2014Publication date: February 12, 2015Applicant: ASTELLAS PHARMA INC.Inventors: Ryota Shiraki, Takahiko TOBE, Shimpei KAWAKAMI, Hiroyuki MORITOMO, Makoto OHMIYA
-
Patent number: 8937087Abstract: [Problem] A compound which is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM) is provided. [Means for Solution] The present inventors have studied a compound which has a dopamine D1 receptor positive allosteric modulating activity and is useful as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like, and they have thus found that a heterocyclic acetamide compound has a dopamine D1 receptor positive allosteric modulating activity, thereby completing the present invention. The heterocyclic acetamide compound of the present invention has a dopamine D1 receptor positive allosteric modulating activity and can be used as an agent for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like.Type: GrantFiled: April 18, 2014Date of Patent: January 20, 2015Assignee: Astellas Pharma Inc.Inventors: Ryota Shiraki, Takahiko Tobe, Shimpei Kawakami, Hiroyuki Moritomo, Makoto Ohmiya
-
Publication number: 20140315963Abstract: [Problem] A compound which is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM) is provided. [Means for Solution] The present inventors have studied a compound which has a dopamine D1 receptor positive allosteric modulating activity and is useful as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like, and they have thus found that a heterocyclic acetamide compound has a dopamine D1 receptor positive allosteric modulating activity, thereby completing the present invention. The heterocyclic acetamide compound of the present invention has a dopamine D1 receptor positive allosteric modulating activity and can be used as an agent for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like.Type: ApplicationFiled: April 18, 2014Publication date: October 23, 2014Applicant: ASTELLAS PHARMA INC.Inventors: Ryota Shiraki, Takahiko Tobe, Shimpei Kawakami, Hiroyuki Moritomo, Makoto Ohmiya
-
Patent number: 8278333Abstract: Object Provided are ?-form crystal, ?-form crystal, and ?-form crystal of a benzoxadiazole derivative, wherein a uniform crystal having sufficient qualities can be obtained with high reproducibility, and they can be anytime supplied as crystals of drug substance for use in producing pharmaceuticals, are particularly suitable for mass synthesis in industrial production, hardly exhibit hygroscopicity and have particularly excellent photo-resistance. Means for Resolution A solving means includes ?-form crystal of 4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole, which shows an endothermic peak at 145 to 150° C. according to a differential scanning calorimeter analysis (DSC analysis) and shows X-ray powder diffraction peaks at 9.8, 11.1, 12.8, 13.3, 17.1, 20.2, 21.2 and 22.3 in 2?(°), and the like.Type: GrantFiled: July 13, 2007Date of Patent: October 2, 2012Assignee: Astellas Pharma Inc.Inventors: Noritaka Hamada, Ryo Mizoguchi, Kuniyuki Sano, Takaaki Sakaida, Yuji Awamura, Yu Iwakawa, Takahiko Tobe, Takashi Sugane
-
Patent number: 8211907Abstract: To provide a compound which is useful as an NMDA receptor antagonist. The present inventors have studied a compound having an NMDA receptor antagonistic action, and confirmed that the fused indane compound of the present invention has an excellent NMDA receptor antagonistic action, thereby completed the present invention. The fused indane compound of the present invention has an excellent NMDA receptor antagonistic action and can be used as a prophylactic and/or therapeutic agent for Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, intractable depression, attention deficit hyperactivity disorder, migraines, or the like.Type: GrantFiled: November 26, 2008Date of Patent: July 3, 2012Assignee: Astellas Pharma Inc.Inventors: Satoshi Hayashibe, Shingo Yamasaki, Nobuyuki Shiraishi, Hiroaki Hoshii, Takahiko Tobe
-
Publication number: 20100267695Abstract: [Problems] To provide a compound which is useful as an NMDA receptor antagonist. [Means for Solution] The present inventors have studied a compound having an NMDA receptor antagonistic action, and confirmed that the fused indane compound of the present invention has an excellent NMDA receptor antagonistic action, thereby completed the present invention. The fused indane compound of the present invention has an excellent NMDA receptor antagonistic action and can be used as a prophylactic and/or therapeutic agent for Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, intractable depression, attention deficit hyperactivity disorder, migraines, or the like.Type: ApplicationFiled: November 26, 2008Publication date: October 21, 2010Applicant: ASTELLAS PHARMA INC.Inventors: Satoshi Hayashibe, Shingo Yamasaki, Nobuyuki Shiraishi, Hiroaki Hoshii, Takahiko Tobe
-
Publication number: 20090203741Abstract: Object Provided are ?-form crystal, ?-form crystal, and ?-form crystal of a benzoxadiazole derivative, wherein a uniform crystal having sufficient qualities can be obtained with high reproducibility, and they can be anytime supplied as crystals of drug substance for use in producing pharmaceuticals, are particularly suitable for mass synthesis in industrial production, hardly exhibit hygroscopicity and have particularly excellent photo-resistance. Means for Resolution A solving means includes ?-form crystal of 4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole, which shows an endothermic peak at 145 to 150° C. according to a differential scanning calorimeter analysis (DSC analysis) and shows X-ray powder diffraction peaks at 9.8, 11.1, 12.8, 13.3, 17.1, 20.2, 21.2 and 22.3 in 2?(°), and the like.Type: ApplicationFiled: July 13, 2007Publication date: August 13, 2009Applicant: ASTELLAS PHARMA INC.Inventors: Noritaka Hamada, Ryo Mizoguchi, Kuniyuki Sano, Takaaki Sakaida, Yuji Awamura, Yu Iwakawa, Takahiko Tobe, Takashi Sugane
-
Publication number: 20070197594Abstract: Provided are compounds which are an NMDA antagonist having a broad safety margin and are useful as a treating agent or a preventing agent for Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic apoplexy, pain, etc. Concretely provided are an amine derivative or its salt characterized in that the amine-containing structure A therein bonds to a 2- or 3-cyclic condensed ring (e.g., indane, tetralone, 4,5,6,7-tetrahydrobenzothiophene, 4,5,6,7-tetrahydrobenzofuran, 7,8-dihydro-6H-indeno[4,5-b]furan, 2,3-dihydro-1H-cyclopenta[1]naphthalene) via X1 (bond or lower alkylene); and an NMDA antagonist containing it as an active ingredient thereof.Type: ApplicationFiled: September 20, 2005Publication date: August 23, 2007Applicant: ASTELLAS PHARMA INC.Inventors: Satoshi Hayashibe, Takatoshi Kanayama, Junya Ohmori, Takahiko Tobe, Kyoichi Maeno, Yoshitsugu Shitaka, Jotarou Suzuki, Shigeki Kawabata, Nobuyuki Shiraishi, Shingo Yamasaki, Daisuke Suzuki, Hiroaki Hoshii
-
Patent number: 7084164Abstract: The invention relates to a triazole derivative with an activity inhibiting glycine transporter and for use as a pharmaceutical drug, and a novel triazole derivative. The inventive triazole derivative has an excellent activity inhibiting glycine transporter and is useful as a therapeutic agent of dementia, schizophrenia, cognitive disorders, or cognitive disorders involved in various diseases such as Alzheimer disease, Parkinson's disease, or Huntington disease or the like, or spasm involved in diseases such as nerve degenerative diseases and cerebrovascular disorders, or the like. Particularly, the pharmaceutical drug is useful for the amelioration of learning disability of dementia and the like.Type: GrantFiled: September 22, 2005Date of Patent: August 1, 2006Assignee: Astellas Pharma, Inc.Inventors: Takahiko Tobe, Takashi Sugane, Wataru Hamaguchi, Itsuro Shimada, Kyoichi Maeno, Junji Miyata, Tetsuya Kimizuka, Takeshi Suzuki, Atsuyuki Kohara, Takuma Morita, Michael Arlt, Hartmut Greiner
-
Patent number: 7034047Abstract: The invention relates to a triazole derivative with an activity inhibiting glycine transporter and for use as a pharmaceutical drug, and a novel triazole derivative. The inventive triazole derivative has an excellent activity inhibiting glycine transporter and is useful as a therapeutic agent of dementia, schizophrenia, cognitive disorders, or cognitive disorders involved in various diseases such as Alzheimer disease, Parkinson's disease, or Huntington disease or the like, or spasm involved in diseases such as nerve degenerative diseases and cerebrovascular disorders, or the like. Particularly, the pharmaceutical drug is useful for the amelioration of learning disability of dementia and the like.Type: GrantFiled: May 19, 2004Date of Patent: April 25, 2006Assignee: Astellas Pharma, Inc.Inventors: Takahiko Tobe, Takashi Sugane, Wataru Hamaguchi, Itsuro Shimada, Kyoichi Maeno, Junji Miyata, Tetsuya Kimizuka, Takeshi Suzuki, Atsuyuki Kohara, Takuma Morita, Michael Arlt, Hartmut Greiner
-
Publication number: 20060025461Abstract: The invention relates to a triazole derivative with an activity inhibiting glycine transporter and for use as a pharmaceutical drug, and a novel triazole derivative. The inventive triazole derivative has an excellent activity inhibiting glycine transporter and is useful as a therapeutic agent of dementia, schizophrenia, cognitive disorders, or cognitive disorders involved in various diseases such as Alzheimer disease, Parkinson's disease, or Huntington disease or the like, or spasm involved in diseases such as nerve degenerative diseases and cerebrovascular disorders, or the like. Particularly, the pharmaceutical drug is useful for the amelioration of learning disability of dementia and the like.Type: ApplicationFiled: September 22, 2005Publication date: February 2, 2006Inventors: Takahiko Tobe, Takashi Sugane, Wataru Hamaguchi, Itsuro Shimada, Kyoichi Maeno, Junji Miyata, Tetsuya Kimizuka, Takeshi Suzuki, Atsuyuki Kohara, Takuma Morita, Michael Arlt, Hartmut Greiner
-
Publication number: 20040214818Abstract: The invention relates to a triazole derivative with an activity inhibiting glycine transporter and for use as a pharmaceutical drug, and a novel triazole derivative. The inventive triazole derivative has an excellent activity inhibiting glycine transporter and is useful as a therapeutic agent of dementia, schizophrenia, cognitive disorders, or cognitive disorders involved in various diseases such as Alzheimer disease, Parkinson's disease, or Huntington disease or the like, or spasm involved in diseases such as nerve degenerative diseases and cerebrovascular disorders, or the like. Particularly, the pharmaceutical drug is useful for the amelioration of learning disability of dementia and the like.Type: ApplicationFiled: May 19, 2004Publication date: October 28, 2004Applicant: YAMANOUCHI PHARMACEUTICAL CO., LTD., MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNGInventors: Takahiko Tobe, Takashi Sugane, Wataru Hamaguchi, Itsuro Shimada, Kyoichi Maeno, Junji Miyata, Tetsuya Kimizuka, Takeshi Suzuki, Atsuyuki Kohara, Takuma Morita, Michael Arlt, Hartmut Greiner
-
Publication number: 20030216385Abstract: The invention relates to a triazole derivative with an activity inhibiting glycine transporter and for use as a pharmaceutical drug, and a novel triazole derivative. The inventive triazole derivative has an excellent activity inhibiting glycine transporter and is useful as a therapeutic agent of dementia, schizophrenia, cognitive disorders, or cognitive disorders involved in various diseases such as Alzheimer disease, Parkinson's disease, or Huntington disease or the like, or spasm involved in diseases such as nerve degenerative diseases and cerebrovascular disorders, or the like. Particularly, the pharmaceutical drug is useful for the amelioration of learning disability of dementia and the like.Type: ApplicationFiled: November 18, 2002Publication date: November 20, 2003Inventors: Takahiko Tobe, Takashi Sugane, Wataru Hamaguchi, Itsuro Shimada, Kyoichi Maeno, Junji Miyata, Tetsuya Kimizuka, Takeshi Suzuki, Atsuyuki Kohara, Takuma Morita, Michael Arlt, Hartmut Greiner